Skin symptoms, severe wheezing, and moderate to severe cardiovascular/neurologic symptoms during an oral food challenge were found to be predictive of SRA. Male ...

Please provide your email address to receive an email when new articles are posted on . Peanuts, tree nuts and shellfish were the most common triggers. 21.3% of patients had no prior history of ...

Study identifies treatable microbiome features in severe asthma, revealing potential for precision antibiotic therapies. Study: Species-level, metagenomic and proteomic analysis of microbe-immune ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Ian is professor ...

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

Blood eosinophil count and fractional exhaled nitric oxide (FeNO) play an important role in selecting biological therapies for severe asthma. This analysis of patient-level data pooled across 22 ...

The Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) has unanimously recommended mepolizumab (Nucala, GlaxoSmithKline) for add-on maintenance treatment in ...

BOSTON -- Patients with severe, uncontrolled asthma had significantly higher odds of improvement in asthma-related sleep disturbances and improvement in activity levels when treated with tezepelumab ...

Researchers investigating the genetics underlying the airway inflammation seen in severe asthma have, for the first time, discovered that proteins that bind to RNA are dysregulated, and drive changes ...

Mepolizumab significantly reduced healthcare resource utilization, including hospitalizations and emergency department visits, in patients with severe eosinophilic asthma over two years. The treatment ...

European Commission approves GSK’s Exdensur for severe asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, February 18, 2026, 09:00 Hrs [IST] GSK plc announced the ...